Author

Steffen Krohn

University Hospital Schleswig-Holstein

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 3 Organism:human· 3 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

Matthias PeippiD· 4 shared Claudia Dorothea BaldusiD· 3 shared Dorothee WinterbergiD· 3 shared Katja KlausziD· 3 shared Monika BrüggemanniD· 3 shared Thomas ValeriusiD· 3 shared Alexander Jochimsen· 2 shared Ammelie Svea BojeiD· 2 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

Matthias PeippORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

CD19xCD3 bispecific T cell engager treatment induces remission in experimental pemphigoid disease

Natalie Groß, Alexander Jochimsen, Sören Dräger, Thomas Theocharis, Andreas Recke, Nina van Beek, Leon F. Schmidt‐Jiménez, Steffen Krohn, Katja Klausz, Katja Bieber, Ralf Joachim Ludwig, Matthias Peipp

The paper tests a CD19xCD3 bispecific T cell engager in a mouse model of pemphigoid disease and finds it induces remission in 45% of treated mice.

Molecular Therapy Advances · Jul 30, 2026Peer-reviewedImmunology

A Novel Natural Killer Cell Expansion Technology for the Development of Cellular Immunotherapies

Ammelie Svea Boje, Anna Langner, Alexander Jochimsen, Carina Lynn Gehlert, Steffen Krohn, Dorothee Winterberg, Sonja Bendig, Eva Maria Murga Penas, Guranda Chitadze, Monika Brüggemann, Lars R. Fransecky, Katharina Diemer, Dirk Bauerschlag, Natalie Baum, Daniela Wesch, , Matthias Peipp

This paper introduces a multifunctional fusion protein that enables efficient ex vivo expansion of NK cells from various sources and enhances their cytotoxic activity against tumor cells.

bioRxiv · Jan 22, 2026 · PreprintImmunology

A novel Fc-optimized antibody drug conjugate targeting CD7 for the therapy of T-cell acute lymphoblastic leukemia

Carina Lynn Gehlert, Denis Martin Schewe, Katja Klausz, Steffen Krohn, Dorothee Winterberg, Fotini Vogiatzi, Ammelie Svea Boje, Natalie Baum, Mona Könecke, Anja Lux, Falk Nimmerjahn, Regina Scherließ, Andreas Humpe, Martin Schrappe, Gunnar Cario, , Matthias Peipp

This paper evaluates a novel Fc-optimized antibody drug conjugate targeting CD7, showing potent anti-leukemia activity in preclinical T-ALL models.

bioRxiv · Oct 30, 2025 · PreprintCancer Biology

Myeloid cell-mediated killing of B-ALL by CD38 and CD20IgA antibody variants is enhanced by CD47/SIRPα interference

Maja Kowol, Marta Lustig, Annette M. Hartmann, Ida C. van der Peet, Marco Jansen, Dorothee Winterberg, Steffen Krohn, Niklas Baumann, Thies Rösner, Sonja Bendig, Alexander Arthur Wurm, Monika Brüggemann, Renate Burger, Kerstin Schmitt, Oliver Valerius, , Thomas Valerius

This study evaluates the efficacy of CD38 and CD20 IgG1/IgA2 antibodies in mediating myeloid cell-mediated killing of B-ALL, showing enhanced activity with CD47/SIRPα blockade.

bioRxiv · Aug 13, 2025 · PreprintCancer Biology